Codexis (CDXS) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Speaker0 As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to your host, Carrie McKim, Director of Investor Relations. Carrie, please go ahead. Speaker1 Thank you, operator. With me today are Doctor. Stephen Dilly, Codexis' Chairman and Chief Executive Officer Georgia Erbez, Chief Financial Officer and Doctor. Stephane Lutz, Senior Vice President of Research. During this call, management will making a nu ...

Financial Data and Key Metrics Changes - Total first quarter revenue was $7,100,000, representing a 45% year-over-year growth [7][17] - Net loss for the quarter was $1,100,000, with adjusted EBITDA at a negative $51,000, compared to a loss of $1,200,000 and $104,000 year-over-year respectively [7][38] - Operating loss decreased to approximately $1,400,000 from $1,800,000 in the same quarter last year [48] Business Line Data and Key Metrics Changes - Revenue growth was driven by key new pharmaceutical projects and health services renewals, as well as the full first quarter contribution from Kyber Data Sciences [7][38] - The Kyber acquisition contributed approximately $1,700,000 or 35% to the revenue growth, with the remaining increase resulting from organic growth in the Life Sciences data business [17][47] Market Data and Key Metrics Changes - The company has approximately $34,000,000 of committed contracted backlog, which includes unearned revenue and unbilled amounts that will be recognized as revenue in future periods [44] - The expected full year 2025 revenue is projected to be between $28,000,000 and $30,000,000, reflecting a growth of 39% to 49% year-over-year [44][50] Company Strategy and Development Direction - The company aims to enhance its offerings by integrating Kyber with its data factory and capitalizing on advanced analytics and predictive capabilities in the life sciences market [10][43] - The company continues to seek accretive and strategic mergers and acquisitions to enhance its financial profile and expand access to pharmaceutical clients [12][43] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2025, highlighting the momentum and opportunities in the market despite a turbulent macroeconomic environment [5][14] - The company is comfortable with its process of integrating new vendors and expects this to be a recurring theme in 2025 and into 2026 [11][42] Other Important Information - The company ended the period with $35,700,000 in cash and marketable securities and $6,800,000 in convertible notes maturing in September 2025 [49] - Adjusted EBITDA is expected to range from negative $1,000,000 to positive $1,000,000, primarily dependent on the speed at which Kyber achieves profitability [44][50] Q&A Session Summary Question: Can you characterize Kyber's revenue stream? - Kyber's revenue is typically based on one-year contracts, and the company is working to implement auto-renewals [22][52] Question: What will determine Kyber's move to profitability? - The expectation is that as Kyber grows its top line, it will flow down to EBITDA, with most expectations driven by revenue growth [25][53] Question: How do you feel about the M&A environment? - The market is bifurcated, with stronger private companies demanding premiums, while VC-backed companies are struggling with valuations, leading to more opportunities for acquisitions like Kyber [27][55] Question: Have you seen any hesitation in new deals due to executive orders affecting the pharma market? - There has been hesitation among companies waiting for FDA approvals, but overall, the company has been insulated from larger executive actions [29][57]

New Fortress Energy (NFE) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Speaker0 Good day, and welcome to the NFE First Quarter twenty twenty five Earnings Call. Today's conference is being recorded. At this time, I will be handing the call over to Matt Reinhardt, Managing Director, for introductory remarks. Speaker1 Good afternoon, everyone. Thank you for joining today's conference call, where we will be discussing our first quarter twenty twenty five results. The call is being recorded and will be availa ...

Financial Data and Key Metrics Changes - Net revenues decreased by $2,800,000 or 85% from $3,300,000 for the three months ended March 31, 2024, to $500,000 for the three months ended March 31, 2025 [8] - Cost of net revenues decreased by $900,000 or 69% from $1,300,000 for the three months ended March 31, 2024, to $2,400,000 for the three months ended March 31, 2025 [10] - Gross margin decreased to 18% for the three months ended March 31, 2025, from 60% for the three months ended March 31, 2024 [11] Business Line Data and Key Metrics Changes - The decrease in net revenues was primarily due to a reduction of $2,300,000 in product sales and a decrease of $500,000 in service revenue [9] - The gross margin for product sales was at negative 120%, mainly due to low volume of product sales [11] Market Data and Key Metrics Changes - The company anticipates that the average selling price of the new 5G chipset will be approximately four times higher than that of the current 4G offering [7] - The company expects to benefit from higher global market demand and market prices in the 5G chip market once sales commence [10] Company Strategy and Development Direction - The company has officially begun the 5G product era and is focused on customer sampling starting this month, leading to volume shipments in Q3 and beyond [4] - The company has accelerated partnerships with renowned partners like Globalstar, Aramco Digital, Samsung, and Kyocera to enhance its 5G initiatives [4][5] - A letter of intent has been signed with Orbit North America to jointly develop and supply a mobile hotspot and FWA gateway utilizing a Verizon certified 5G module [5] Management's Comments on Operating Environment and Future Outlook - Management expressed excitement about the impact of 5G on the company's income statement and balance sheet starting from the second half of the year [7] - The company is focused on driving innovation and supporting the global transition to 5G solutions, aiming for substantial growth based on the 5G chipset launch [12] Other Important Information - The company closed the quarter with cash and cash equivalents of $1,000,000, net accounts receivable of $4,500,000, and net inventory of $3,100,000 [11] - The company has filed shelf registrations providing up to $200,000,000 in capacity, including a $75,000,000 at-the-market facility to enhance financial flexibility [11] Q&A Session Summary Question: Follow-up on the partnership with Orbit for the 5G mobile hotspot - Management expressed excitement about the Orbit relationship, indicating it will involve collaboration for multiple operators and products [16][18] Question: Details on the sampling and commercial shipments for 5G - Management confirmed that sampling will commence with six primary customers, with plans to move into commercial shipments in the second half of the year [23][25] Question: Supply chain readiness for volume production - Management indicated confidence in the supply chain's capability to transition to volume production, leveraging existing relationships [26] Question: Operational expenses outlook for the second half of the year - Management stated that operational expenses are not expected to scale at the same rate as revenue, with tight cost control processes in place [28]

Financial Data and Key Metrics Changes - The cash operating expenses for Q1 2025 totaled $2.9 million, a decrease from $4.2 million in Q1 2024, indicating a reduction in personnel and general administrative expenses [17][18] - The company has adjusted its 2025 expected cash operating expense guidance to a range of $17 million to $19 million [17] Business Line Data and Key Metrics Changes - The nephro CRRT trial has seen a reduction in study size from 166 patients to 70 patients, which is expected to shorten the study completion time [4][5] - The company has added three new clinical study sites that are actively screening patients, with five more expected by mid-year [6][12] Market Data and Key Metrics Changes - There is an ongoing inquiry from healthcare providers regarding the availability of Nefamostat due to shortages of citrate and potential supply chain issues with heparin [7] Company Strategy and Development Direction - The company is focused on completing the nephro study by the end of 2025 and believes that the new site engagement will significantly contribute to study enrollment [11][15] - The company is exploring a compassionate use IDE for Nefamostat, responding to requests from institutions for patients who do not respond well to current anticoagulants [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the low clinical, regulatory, and commercial risks associated with the nephro program, citing a strong track record of nafamostat's efficacy and safety [15] - The company anticipates that the expanded enrollment criteria will lead to increased activity at both legacy and new sites, although immediate results from legacy sites have not yet materialized [24][30] Other Important Information - The company completed a PIPE financing structured in three tranches, with the first tranche received and the remaining tranches contingent on patient enrollment milestones [19] Q&A Session Summary Question: Has the broader enrollment criteria started to translate into increased enrollment? - Management noted that while there has been increased activity at the sites due to broader criteria, it has not yet translated into new patients from legacy sites [24][25] Question: What are the challenges faced by legacy sites in enrolling patients? - The legacy sites are primarily dependent on surgical ICUs or cardiothoracic ICUs, which limits their patient pool despite the expanded criteria [29]

Financial Data and Key Metrics Changes - For Q1 2025, the company reported cash of $13.3 million, with an operating cash flow of $2.3 million, resulting in a monthly cash burn of approximately $800,000, down from $1.1 to $1.2 million last year [5][6] - The company forecasts a monthly cash burn of about $1 million for the remainder of the year, indicating a strong balance sheet with over a year of cash available [6] Business Line Data and Key Metrics Changes - The company is in the final stages of the verification and validation phase of its robotic system development, which has allowed for a reduction in variable costs [5] - The company has 27 full-time employees focused on ongoing R&D to achieve set milestones [5] Market Data and Key Metrics Changes - The orthopedic surgery market is highly consolidated, with Stryker holding a significant market share of approximately 70% with its Mako robot [15][16] - The company aims to capitalize on the generational shift in orthopedic surgery, as many new surgeons are being trained on robotic systems, which could lead to a significant market opportunity [17] Company Strategy and Development Direction - The company received FDA clearance for its embossed total TKA system, marking a significant milestone in its history [8][10] - The company plans to conduct a pilot placement with a major institution in the U.S. to demonstrate the system's value proposition and clinical performance [10] - The company is also preparing for a multicenter clinical trial in India, which will be the first clinical investigation involving autonomous robotic total knee surgeries on live patients [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the potential impact of robotic precision and efficiency in orthopedic surgeries [13][19] - The company believes it is at the forefront of a paradigm shift in orthopedic surgery, with plans to demonstrate its capabilities in live patient cases [14][19] Other Important Information - The company is actively showcasing its system with key opinion leaders and preparing for additional placements, emphasizing a slow and methodical rollout to ensure high service levels [11] - The company is exploring capital opportunities to accelerate growth, indicating a need for additional capital to support commercialization efforts [62] Q&A Session Summary Question: Can you provide more detail on timelines for the U.S. and India regarding technical and regulatory hurdles? - The company expects to perform live patient surgeries in India within 90 business days and anticipates the first placement in the U.S. to occur in Q2 or early Q3 [25][26] Question: What differentiators will allow Monogram to compete with Stryker? - The company aims to focus on accuracy, safety, and minimal surgeon fatigue, with plans to leverage AI for landmark identification and improve tensioning efficiency [31][33][39] Question: Can you provide more color on system enhancements? - Significant enhancements have been made to the feed rate and software of the robot, with ongoing internal testing to ensure safety and performance [50][51] Question: Is the domestic launch considered a trial or full commercial launch? - The launch is termed a pilot launch, allowing for real-world evaluation and surgeon training before broader commercialization [53][55] Question: What are the capital needs in light of upcoming clinical trials? - The company is actively exploring capital opportunities to accelerate growth, with strong interest from investors [62][63]

Financial Data and Key Metrics Changes - Net sales for Q1 2025 totaled $26.9 million, a decrease of 21.4% from $34.2 million in Q1 2024, impacted by delays in customer approvals and manufacturing efficiencies [15][16] - Gross profit for Q1 2025 was $3.1 million, or 11.1% of net sales, compared to $5.4 million, or 15.9% in the same quarter last year, due to lower sales and reduced facility utilization [16] - Adjusted EBITDA for Q1 2025 was negative $1 million, down from $1.6 million in Q1 2024, reflecting ongoing operational challenges [18] Business Line Data and Key Metrics Changes - The aerospace and defense segment faced revenue impacts due to the closure of the Blue Earth facility and delays in customer approvals for the transfer of programs to the Bemidji facility [4][5] - Customer backlog has stabilized as of March 31, 2025, consistent with the year-end 2024 backlog, with expectations for improved order volume as approvals are completed [16] Market Data and Key Metrics Changes - The company is closely monitoring supply chain strategies as customers evaluate their operations in light of tariff uncertainties, particularly regarding facilities in China and Mexico [6][7] - Opportunities are emerging in China as companies seek to consolidate manufacturing within the region, aligning with the company's nearshoring strategy [7] Company Strategy and Development Direction - The company is focused on reducing operating costs and aligning operations with market demand to drive sustainable long-term EBITDA growth [21] - A three-tier global manufacturing strategy across the US, Mexico, and China is in place to enhance competitiveness and operational flexibility [10][11] - The company is investing in engineering expertise and product innovation, particularly in fiber optic technologies, to meet evolving customer needs [24][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the stabilization of customer backlogs and the potential for revenue recovery in the second half of 2025 [5][9] - The company is committed to monitoring geopolitical uncertainties and adjusting strategies to mitigate risks associated with tariffs and supply chain disruptions [6][7] Other Important Information - The company plans to further reduce inventory investments throughout 2025, aiming to improve cash flow and operational efficiency [19][21] - The focus on sustainability and innovation in fiber optics is expected to align with industry trends and customer demands for environmentally friendly solutions [26][27] Q&A Session Summary Question: What are the expectations for future revenue recovery? - Management expects revenue recovery in the second half of 2025 as customer approvals are completed and operational efficiencies improve [5][9] Question: How is the company addressing tariff impacts? - The company is closely monitoring tariff implications and adjusting pricing and sourcing strategies to mitigate adverse effects [7] Question: What innovations are being pursued in product development? - The company is advancing fiber optic technologies, including EBX and AOX, to enhance product performance and meet customer needs [24][26]

Financial Data and Key Metrics Changes - For Q1 2025, revenues were $25,000, a decrease from $35,000 in the same period last year [6] - Deferred revenues for Q1 2025 were $150,000 compared to nil in Q1 2024, indicating a timing difference in revenue recognition [6] - The loss from operations for Q1 2025 was $4,800,000, compared to $4,100,000 for Q1 2024 [7] - The net loss for Q1 2025 was $5,300,000 or $0.64 per share, compared to a net loss of $2,200,000 or $0.33 per share in Q1 2024 [7] - Cash used in operating activities in Q1 2025 was $2,800,000, with cash, cash equivalents, and marketable securities totaling $9,100,000 and no outstanding debt [8][19] Business Line Data and Key Metrics Changes - The lead clinical stage candidate, BRTX-one hundred, is being evaluated in a Phase II trial for chronic lumbar disc disease (CLDD) [10] - Preliminary data from the trial shows positive trends in safety and efficacy, with no serious adverse events reported [11][12] - The FDA granted Fast Track designation for BRTX-one hundred, facilitating its development and review process [13] Market Data and Key Metrics Changes - The company is developing ThermoStem, a cell-based therapy targeting obesity and metabolic disorders, using brown adipose-derived stem cells [14] - The company has built a comprehensive patent portfolio to protect its intellectual property in both US and international markets [15] Company Strategy and Development Direction - The company is focused on advancing its two core clinical development programs: BRTX-one hundred and ThermoStem [16] - There are ongoing discussions regarding a potential licensing agreement for the ThermoStem metabolic disease programs [15][19] - The company aims to leverage positive preliminary data to potentially shorten the regulatory process for BLA approval [45] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing Phase II trial for BRTX-one hundred, expecting data to remain consistent with previous trends [17] - The company is actively managing resources while executing strategic goals, ending the quarter with a strong financial position [19] Other Important Information - The company is preparing for a presentation of data from 45 subjects at an upcoming conference in June [26] - Management emphasized the importance of maintaining a clean and valid data set for the trial [36] Q&A Session Summary Question: Clarification on efficacy endpoint - Management confirmed that the primary endpoint is safety, with a secondary efficacy endpoint of greater than or equal to 30% improvement [22] Question: Interim analysis status - Management stated that an interim analysis is still a potential option but has not been determined yet [23][24] Question: Enrollment pace and characteristics - Management indicated that enrollment is picking up due to new recruitment strategies and that they expect to counteract any summer slowdown [36] Question: FDA emphasis on pain or function - Management noted that both pain reduction and functional improvement are being collected, with ongoing discussions with the FDA [38] Question: Morphological changes observed - Management provided details on encouraging morphological changes observed in patients, including increased hydration and decreased protrusion size [42][44]

Financial Data and Key Metrics Changes - Revenue for the first quarter of 2025 was $23.8 million, up from $20.2 million in the fourth quarter and $18.3 million in the prior year period, reflecting a 30% year-over-year growth [26][27] - Operating EBITDA increased to $12.3 million for the first quarter, compared to $10.7 million in the prior year period, primarily due to the NJR acquisition [28][29] - The company reported a GAAP net loss attributable to stockholders of $15.3 million [28] Business Line Data and Key Metrics Changes - The acquisition of rooftop assets from NJR positively impacted revenue and operating EBITDA, with the company owning and operating approximately 85,000 home solar assets and servicing around 60,000 residential solar systems [5][6] - Portfolio O&M expenses were $3.9 million in the first quarter, down from $5.3 million in the fourth quarter, indicating a sequential decline of over 25% [27] - SG&A expenses were $14.1 million in the first quarter, down from $15.5 million in the fourth quarter but up from $13.5 million in the prior year period [27] Market Data and Key Metrics Changes - The company is experiencing a cautious approach to new growth opportunities due to uncertainty in the market, which has affected cash burn and revenue collection timing [7][29] - The New Jersey market has deep liquidity in the SREC market, which is expected to continue supporting revenue generation [39] Company Strategy and Development Direction - The company aims to achieve positive free cash flow through growth in solar installations, prudent cost containment, and disciplined acquisition strategies [6][11] - Spruce Pro is identified as a key revenue driver, leveraging existing infrastructure to provide services to third-party owners of solar assets [15][16] - The company is focused on operational enhancements through strategic sourcing and better vendor management to improve efficiency and margin expansion [11][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate current market challenges, emphasizing the predictability of cash flows from existing solar assets [20][23] - The company is optimistic about achieving profitability and positive cash flow through reduced spending and operational efficiencies [31] - Management highlighted the unique position of Spruce Power as a third-party operator, which mitigates risks associated with aggressive customer acquisition strategies [23][44] Other Important Information - The company has approximately $96.5 million in total cash, with $61.9 million being unrestricted cash at the end of the first quarter [29] - The Board of Directors has approved the renewal of the company's share repurchase program [22] Q&A Session Summary Question: What is the scale of revenue opportunity for Spruce Pro and the lead times to build that business? - Management indicated that Spruce Pro is a capital-light endeavor with a deep pipeline of prospects and expects to make further announcements in the next quarter [35][36] Question: What does the refinancing environment look like for the FC1 loan? - Management expressed confidence in obtaining like-for-like terms for refinancing and is exploring more favorable credit options [38] Question: Why are SRECs for the SP Five acquisition so high compared to other assets? - Management explained that New Jersey has deep liquidity and high prices in the SREC market, which is expected to continue [39] Question: What drove the decision for the CFO transition? - Management noted that the CFO's decision to move to a private company aligns with her personal objectives, and they are actively searching for a replacement [40][41] Question: How durable is the business model compared to industry peers under the new administration? - Management highlighted that being a third-party operator allows them to mitigate risks associated with new installations and tax credits, maintaining a strong liquidity profile [43][44]

Financial Data and Key Metrics Changes - The company reported revenues of $20.1 million for Q1 2025, a 42.5% increase compared to $14.1 million in Q1 2024 [5][20] - Bookings increased by 13.6% to $22.2 million compared to $19.6 million in the same period last year [22] - The net loss for Q1 2025 was $1.9 million, slightly higher than the loss of $1.8 million in Q1 2024 [21] - EBITDA for the quarter was a loss of $3.2 million, compared to a loss of $1.9 million in the prior year [22] Business Line Data and Key Metrics Changes - Total units sold increased by 45% to 1.5 million, primarily driven by the flagship ARC franchise [5] - The mobile segment saw significant growth, with ARC Ultimate Mobile Edition achieving 4.8 million downloads and an average daily active user count of approximately 144,000 [7][20] Market Data and Key Metrics Changes - PC gaming accounted for approximately 48% of revenue in 2024, compared to 41% from consoles [24] - The company noted that the mobile game segment helps offset broader economic impacts, as it lowers the barriers to entry for new players [24] Company Strategy and Development Direction - The company is focused on expanding its content portfolio and diversifying revenue streams, including a new short drama business [10][19] - Upcoming releases and announcements are planned to celebrate the ten-year anniversary of the ARC franchise, with a focus on engaging a broader audience [26] - The company aims to invest in scalable growth opportunities across adjacent genres and emerging platforms [26] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the impact of tariffs on the business, noting that while direct impacts are limited, indirect effects could influence consumer spending [23][25] - The gaming industry has historically shown resilience in the face of economic uncertainty, and the company remains confident in its ability to adapt [25] Other Important Information - The company has signed an MOU with MacMetrix Inc. to co-develop at least 10 short drama series over the next twelve months [10][34] - The company is actively exploring new business opportunities and expanding its indie publishing label, Wandering Wizard [19] Q&A Session Summary Question: Can you discuss your approach to revenue diversification? - The company is exploring and investing in new games and businesses, including a short drama initiative and several new game releases [28][30] Question: What are the revenue implications of the MOU with Mega Matrix? - It is too early to measure potential revenue contributions, but the MOU involves co-developing at least 10 drama series over the next year [31][34] Question: Can you elaborate on the increase in advertising and marketing costs? - Marketing expenditures have increased due to a larger portfolio and participation in events like GDC, but the company does not expect such increases to continue in the upcoming quarters [36][38] Question: How should investors view the approach to achieving positive net income? - The company focuses on cost control and diversified monetization strategies, including outsourcing development and expanding into new revenue streams [39][40]